BioSpace News Archive

FDA

Pfizer/BioNTech COVID-19 Vaccine Wins EUA in Young Teens

The U.S. FDA expanded the Emergency Use Authorization for the Pfizer and BioNTech vaccine to include adolescents ages 12 to 15 after clinical data showed 100% efficacy response.

May 11, 2021
·
3 min read
·
Alex Keown
Business

Three Companies Land Fresh Funds to Advance Pipelines

2021 is shaping up to be another banner year for biotech companies as they advance the next gen technologies and therapeutics for the health of all. Here’s a few raking in cash for their programs today.

May 11, 2021
·
3 min read
·
Kate Goodwin
Business

Lilly Intensifies RNA-Focused Drug Development with MiNA Therapeutics’ saRNA Platform

Eli Lilly announced a drug development collaboration with MiNA Therapeutics Limited focusing on five novel drug candidates that could be worth up to $245 million.

May 11, 2021
·
2 min read
·
Alex Keown
Business

Biogen Pushes Deeper into Gene Therapy with Capsigen Collaboration

Biogen and Capsigen forged a strategic collaboration to engineer novel adeno-associated virus (AAV) capsids that have the potential to become transformative gene therapies that treat underlying genetic causes of various central nervous system and neuromuscular disorders.

May 11, 2021
·
2 min read
·
Alex Keown
Bio NC

2021 COVID-19 News: India Variant a Global Concern, Low Risk of Serious Long Term Effects and More

Please check out the biopharma industry’s COVID-19 stories that are trending for May 11, 2021.

May 11, 2021
·
5 min read
·
BioSpace Editorial Staff
Deals

“Organism Company” Ginkgo Bioworks Lands Massive SPAC Deal

Biotechnology firm Ginkgo Bioworks is going public via a merger with Soaring Eagle Acquisition Corp.

May 11, 2021
·
3 min read
·
Mark Terry
Drug Development

Cutting-Edge Tech: Highlights from the American Society of Gene & Cell Therapy

The 24th Annual meeting of the American Society of Gene & Cell Therapy presents cutting-edge work in the booming area of gene and cell therapy. Here’s a look at a few of the highlights.

May 11, 2021
·
4 min read
·
Mark Terry
Drug Development

FDA Clears Samus Drug for Glioma Phase Ib Study

Clearance of the IND allows Samus to proceed with a Phase Ib trial to assess the safety, tolerability and pharmacokinetics of PU-AD in a small group of patients with recurrent malignant glioma.

May 11, 2021
·
2 min read
·
Brandon May
Business

Dante Labs announces appointments of Paul Jones, Simon Partridge and Christian Bourne to turbo-charge global population genomics programmes

Paul Jones, Simon Partridge and Christian Bourne, previously from Illumina and Genomics England, have joined Dante Labs in its new Cambridge, UK office to spearhead its ground-breaking global population genomics offer

May 11, 2021
·
3 min read
Sequana Medical Announces Strong Top-Line Results from RED DESERT alfapump DSR® Study and Expansion of DSR® Development Programme

Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces positive top-line results from the RED DESERT study with repeated dose alfapump DSR® therapy in diuretic-resistant heart failure patients.

May 11, 2021
·
13 min read